Irloxacin

Drug Profile

Irloxacin

Alternative Names: E 3432

Latest Information Update: 17 Feb 2006

Price : $50

At a glance

  • Originator Esteve
  • Developer Esteve; Innothera
  • Class Antibacterials; Quinolones; Small molecules
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Bacterial infections; Obstetric and gynaecological infections

Most Recent Events

  • 16 Oct 1998 Suspended-III for Bacterial infections in Spain (Topical)
  • 29 May 1998 Suspended-preclinical phase for Obstetric and gynaecological infections in France (Unknown route)
  • 30 Jul 1996 Phase-III clinical trials for Bacterial infections in Spain (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top